<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00363337</url>
  </required_header>
  <id_info>
    <org_study_id>1-Parker</org_study_id>
    <nct_id>NCT00363337</nct_id>
  </id_info>
  <brief_title>A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lindner Center of HOPE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lindner Center of HOPE</source>
  <brief_summary>
    <textblock>
      The specific aim of this study is to obtain preliminary evidence of the acute effectiveness
      and tolerability of aripiprazole in the treatment of bipolar depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>per protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale Modified for Bipolar Illness (CGI-BP)</measure>
    <time_frame>per protocol</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Bipolar Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>open label treatment with aripiprazole</description>
    <other_name>Abilify</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects must have bipolar I, II or NOS disorder as defined by DSM-IV-TR; must have
             clinical significant depressive symptoms and have failed one or more mood stabilizer
             trials; may or may not be receiving antimanic or mood stabilizing medications;
             subjects or legally authorized representative must sign the Informed Consent document
             after the nature of the trial has been fully explained; if female, subjects must be
             postmenopausal, surgically incapable of childbearing or practicing medically
             acceptable effective method(s) of contraception.

        Exclusion Criteria:

          -  subjects who do not have bipolar disorder by DSM-IV criteria; subjects with current
             DSM-IV Axis I diagnosis of delirium, dementia, amnesia or other cognitive disorders or
             a psychotic disorder; subjects with serious general medical illness; subjects who are
             allergic to or have demonstrated hypersensitivity to aripiprazole; women who are
             pregnant or nursing; subjects who have received an experimental drug or used an
             experimental device within 30 days; subjects who have a history of neurologic
             malignant syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan L McElroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE Jr. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007 Aug;101(1-3):275-81. Epub 2007 Jan 16.</citation>
    <PMID>17229469</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2006</study_first_submitted>
  <study_first_submitted_qc>August 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan McElroy</name_title>
    <organization>Lindner Center of HOPE</organization>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Bipolar Depression</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Bipolar I</keyword>
  <keyword>Bipolar II</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

